KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Resmed (RMD) Accounts Payables (2016 - 2025)

Resmed (RMD) has disclosed Accounts Payables for 16 consecutive years, with $250.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables rose 13.66% year-over-year to $250.4 million, compared with a TTM value of $250.4 million through Dec 2025, up 13.66%, and an annual FY2025 reading of $278.2 million, up 17.01% over the prior year.
  • Accounts Payables was $250.4 million for Q4 2025 at Resmed, down from $266.8 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $278.2 million in Q2 2025 and bottomed at $117.2 million in Q1 2021.
  • Average Accounts Payables over 5 years is $193.7 million, with a median of $179.5 million recorded in 2022.
  • The sharpest move saw Accounts Payables fell 5.33% in 2023, then skyrocketed 57.69% in 2024.
  • Year by year, Accounts Payables stood at $163.4 million in 2021, then increased by 19.98% to $196.0 million in 2022, then rose by 3.26% to $202.4 million in 2023, then increased by 8.85% to $220.3 million in 2024, then rose by 13.66% to $250.4 million in 2025.
  • Business Quant data shows Accounts Payables for RMD at $250.4 million in Q4 2025, $266.8 million in Q3 2025, and $278.2 million in Q2 2025.